Layout Table~~~~1449~1449~~

Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012~
Published by Visiongain, February 2007

The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs.

~Published by Visiongain, February 2007

The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs.

Two main themes that run through this report: patent loss for leading biotech drugs and the use of technology to enable newer drugs to be more effective. Central to both of these matters is the perception that new drugs rely on old delivery technologies to get past the regulatory authorities, whereas old drugs look to new techniques to survive. This report will examine and challenge that approach; visiongain suggests that pharmaceutical companies should look to new drug delivery systems as they develop new drugs, in order to make the most out of these technologies.

- Revenue forecasts for the biological drug delivery market
- Drivers and restraints of the market are identified and discussed
- An analysis of strengths, weaknesses opportunities and threats (SWOT) for the biological drug delivery market
- Future targets for drug delivery technology
- Summaries and analysis of the leading drug delivery companies and their pipelines
- Special focus on oral drug delivery and injection technologies
- An assessment of potential advances, including the challenge of RNA delivery

In stark contrast to the pharmaceutical market as a whole, which is exhibiting single digit growth, the biotech market is still growing significantly with constantly innovative products. The proven methods, such as intravenous infusion and intra-muscular/subcutaneous injection, have remained the standard mode of administration, whereas the novelty has come from new improved protein therapeutics. This situation may be set to change, however, as key products lose patent protection and the market for some biotech drugs becomes more congested.

The report answers key questions such as:
- Which drug delivery companies are likely to be at the forefront of Biotech launches?
- What will be the revenue impact of altering the drug delivery method of patented drugs?
- What will be the revenue in 2012 for biotch drugs using novel drug delivery methods?
- How will the regulatory rulings involving Biosimilar products effect innovation?
- Understand the effect of nanotechnology on the drug delivery methods of biotech drugs

This report includes visiongain's predictions of the Top 10 drugs most likely to be targetted for Biogenerics and the impact on revenue to their current manufacturers.

With Wyeth and AstraZeneca this week signing technology deals, this market is hot. This report will keep you up todate and fully informed of the latest developments in your marketplace.

Table of Contents ~Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012 (Single user License PDF)|863|Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012 (Department License PDF)|864|Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012 (Company wide license PDF)|865|~1449~2692~~

Drug Delivery Systems~
Published by Takeda Pacific, September 2006

US Market Outlook, Advances for Pharma, Biotech & Medical Devices

This research study is about drug delivery systems. It provides readers with relevant information, insights and analysis. This important medical opportunity is assessed in terms of technical and business areas. The participating companies are mapped to show where they fit in the industry landscape. This study reviews the kinds of drug delivery systems that are being used by pharma, biotech or medical device companies.

The report discusses the broad range of drug delivery systems, the technical advances and the applications that drug makers might use. Key advances include orally dissolving tablets and film strips, needle- and needle-free injection systems, transdermal patches, transmucosal delivery, RNAi, drug-coated stents, PEG, nanotechnology, liposomes, monoclonal antibodies, gene delivery, and implants, which all contribute to the many ways that drugs or therapies can be delivered. Drug delivery systems are reviewed in terms of approaches used for delivering drugs targeting major diseases including cardiovascular, cancer, asthma, diabetes, and the central nervous system among others.
~ Published by Takeda Pacific, September 2006

US Market Outlook, Advances for Pharma, Biotech & Medical Devices

Abstract

This research study is about drug delivery systems. It provides readers with relevant information, insights and analysis. This important medical opportunity is assessed in terms of technical and business areas. The participating companies are mapped to show where they fit in the industry landscape. This study reviews the kinds of drug delivery systems that are being used by pharma, biotech or medical device companies.

The report discusses the broad range of drug delivery systems, the technical advances and the applications that drug makers might use. Key advances include orally dissolving tablets and film strips, needle- and needle-free injection systems, transdermal patches, transmucosal delivery, RNAi, drug-coated stents, PEG, nanotechnology, liposomes, monoclonal antibodies, gene delivery, and implants, which all contribute to the many ways that drugs or therapies can be delivered. Drug delivery systems are reviewed in terms of approaches used for delivering drugs targeting major diseases including cardiovascular, cancer, asthma, diabetes, and the central nervous system among others.


This market study shows that drug delivery technologies can help drug makers overcome some of their big challenges. The drug industry continues to see the commercial demise of major branded drugs that reach their patent expiration date. Billions of dollars in revenues are lost to generic drug makers each year. The technology can be used as part of a ‘line extension’ strategy to extend the commercial life of their profitable products. Drug delivery can help ‘rescue’ drug projects with technical challenges by using a customized delivery system.


This report discusses the above topics with interesting and useful findings. The study estimates that the US drug delivery market value might reach nearly $85 billion by 2010. The research includes over 235 key alliances and M&As through 2006. This study uses 29 figures and tables to illustrate the findings or trends. The profiles about companies important to the expanding drug delivery market include detailed information about their business and technical activities.


Table of Contents~Drug Delivery Systems%3A PDF Single User License|201|Drug Delivery Systems%3A PDF Site License|202|~1449~1703~~